Granules India finalizes acquisition of Senn Chemicals

Granules India Limited (BSE: 532482) announced the successful closing of its acquisition of Senn Chemicals AG, a Swiss-based Contract Development and Manufacturing Organization (CDMO), specializing in peptide development and manufacturing. This acquisition marks a strategic move for Granules into the fast-growing peptide therapeutics segment and CDMO space, following a definitive agreement signed in February. Senn Chemicals, founded in 1963, specializes in Liquid-Phase and Solid-Phase Peptide Synthesis, serving pharmaceutical, cosmetic, and theragnostic markets. The acquisition enhances Granules' global footprint, providing access to a regulated market client base and specialized scientific talent. Granules anticipates accelerated development and manufacturing of GLP-1 receptor agonists and other peptide-based APIs, addressing the growing demand in the anti-diabetic and anti-obesity therapeutic areas. Stifel Nicolaus India served as the exclusive financial advisor to Granules India on the transaction.